| Size | Price | |
|---|---|---|
| 250mg | ||
| Other Sizes |
| Targets |
Dermabond does not target a specific biological receptor or enzyme. It acts as a tissue adhesive through polymerization of the cyanoacrylate monomer upon contact with moisture on the skin surface. The polymerized adhesive forms a flexible, waterproof barrier that holds wound edges together and provides protection against bacterial contamination.
|
|---|---|
| ln Vitro |
In vitro, Dermabond demonstrates antibacterial properties. It forms a polymerized barrier upon contact with moisture. It is used as a tissue adhesive in wound closure studies. Its strength and flexibility are assessed in mechanical testing. Its antibacterial activity is evaluated against various bacterial strains.
|
| ln Vivo |
Dermabond is used in vivo as a tissue adhesive for wound and surgical incision closure. It provides a strong, flexible, and waterproof barrier that holds wound edges together. It has antibacterial properties that may reduce the risk of infection. It is used in clinical settings and animal models of wound healing.
|
| Enzyme Assay |
In vitro assays for Dermabond typically involve evaluating its polymerization kinetics, adhesive strength, and antibacterial activity. Polymerization is assessed by measuring setting time. Adhesive strength is measured by tensile or shear testing. Antibacterial activity is evaluated by zone of inhibition or broth microdilution assays against various bacterial strains. Cytotoxicity is assessed in cell culture.
|
| Cell Assay |
Cell-based assays for Dermabond involve culturing fibroblasts or keratinocytes in appropriate media. Cells are exposed to Dermabond or its degradation products. Cytotoxicity is assessed by MTT or LDH release assays. Wound healing is evaluated by scratch wound assays. Inflammatory response is assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo animal experiments for Dermabond typically involve creating incisions or wounds in animal models (e.g., rats, pigs) and applying the adhesive for wound closure. Wound healing is assessed by measuring wound strength, cosmetic outcome, and histology. Infection rates are monitored. Antibacterial activity is evaluated in infected wound models. Pharmacokinetics are not applicable as it is a topical adhesive.
|
| ADME/Pharmacokinetics |
Dermabond (molecular weight 209.29, formula C12H19NO2) is a topical tissue adhesive. It is applied directly to the skin surface and polymerizes upon contact with moisture. It is not absorbed systemically in significant amounts. Detailed pharmacokinetic data are not applicable as it is a topical device rather than a systemically absorbed drug.
|
| Toxicity/Toxicokinetics |
Dermabond is generally well-tolerated. Local side effects may include skin irritation, allergic reactions, and wound dehiscence. It is contraindicated in patients with known hypersensitivity to cyanoacrylates. Comprehensive toxicological evaluation has been conducted for regulatory approval. It is FDA-approved for topical wound closure.
|
| Additional Infomation |
Dermabond has been used in basic scientific research on wound healing.
Dermabond (2-Octyl cyanoacrylate) (CAS#: 133978-15-1) is a tissue adhesive used for wound and surgical incision closure. It has antibacterial properties and is used in wound healing studies. It received FDA approval in 1998. Molecular weight: 209.29, formula: C12H19NO2. |
| Molecular Formula |
C12H19NO2
|
|---|---|
| Molecular Weight |
209.2847635746
|
| Exact Mass |
209.141
|
| CAS # |
133978-15-1
|
| Related CAS # |
152965-95-2
|
| PubChem CID |
9815689
|
| Appearance |
Colorless to light yellow liquid（Density：0.956±0.06 g/cm3）
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
297.6±23.0 °C at 760 mmHg
|
| Flash Point |
137.2±9.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.451
|
| LogP |
3.23
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
262
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCOC(C(C#N)=C)=O
|
| InChi Key |
CQVWXNBVRLKXPE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H19NO2/c1-4-5-6-7-8-11(3)15-12(14)10(2)9-13/h11H,2,4-8H2,1,3H3
|
| Chemical Name |
octan-2-yl 2-cyanoprop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~79.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7783 mL | 23.8914 mL | 47.7829 mL | |
| 5 mM | 0.9557 mL | 4.7783 mL | 9.5566 mL | |
| 10 mM | 0.4778 mL | 2.3891 mL | 4.7783 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
